Dry Age-Related Macular Degeneration – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Age-related macular degeneration (AMD) is a progressive, degenerative disease that frequently results in a large scotoma in the central visual field, causing fixation and reading difficulties. Dry Age-Related Macular Degeneration is caused by the appearance of small yellow deposits called drusen, which form under the retina. These are the retina's accumulated waste products, which can grow in size. This can cause the retinal cells in the macula that process light to die, resulting in blurred vision.
·
In the United States, approximately 11 million
individuals are affected by AMD alone, with a global prevalence of 170 million.
Thelansis’s “Dry Age-Related Macular
Degeneration Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2021 To
2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Dry Age-Related Macular Degeneration
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Dry Age-Related Macular Degeneration across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Dry Age-Related Macular Degeneration Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment